Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03473925
Title Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

prostate cancer

lung non-small cell carcinoma

colorectal cancer

Therapies

Navarixin + Pembrolizumab

Age Groups: senior | adult
Covered Countries USA | CAN


No variant requirements are available.